PHARMIDABLE
ActiveSummary
The computed 12-month bankruptcy probability of PHARMIDABLE is 3.0% (moderate). The 2024 annual accounts show equity of €31,742 and a net result of -€28,258. Its solvency ranks better than 25% of 26041 sector peers (fiscal year 2024). The company has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2024
Axes
Profitability14
Solvency29
Growth-
Track record67
Bankruptcy probability, 12 months
3.0%
Moderate
0%0.5%1.5%4%10%≥ 25%
Credit up to €1,000 at 30 days only on tighter terms
Liquidity short (current ratio 0.87; short-term debt: 30.5% and cash: 4.8% of total assets), and 95.9% of the assets are financed with debt.
Credit check for your own amount and term
Open the credit simulator : see how the verdict changes with amount, term and advance.
Signals
Five signals. The signal on the left, the evidence on the right.
+raises risk○neutral
raises risk · Young company
A young company has little track record yet and statistically fails more often than an established one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Retail trade (NACE 47)
about 45% more bankruptcies
← fewer bankruptcies
more bankruptcies →
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2024Solvency, return and age of the figures
Solvency
4.1%
Return on assets
-3.6%
Age of the figures
21 mo
neutral · Filed after the deadline
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 03-10-2025, 64 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 1 filingDeviation from the deadline
2024
64 d late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its 2024 accounts 64 days after the deadline; the sector median for financial year 2024 is on the deadline day, and 46% of the sector filed late.
Checked, nothing found (1)
History
Go further with this company
How much credit can you give this customer, and on what term?Credit simulator What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file How does this company compare with its sector?Sector benchmark Roughly what is this company worth?Value indication What held for this company on a given day: board, seat, name?Company as of a date
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2024, micro schema
Equity
€31,742
Total assets
€775,771
Net result
-€28,258
Working capital
-€29,920
Turnover and EBIT margin not published: the micro schema does not require them.
Balance-sheet composition
Assets €775,771
Fixed assets
€568,785
Current assets
€206,985
Equity and liabilities €775,771
Equity
€31,742
Debt
€744,029
Debt finances 95.9% of the balance-sheet total.
Key figures and ratios
EBITDA
-€12,281
Cash flow
€311
Current ratio
0.87
Quick ratio
0.61
Debt to equity
23.44
ROE
-89.0%
ROA
-3.6%
Interest coverage
-0.99
Debt ≤ 1 year
€236,906
Debt > 1 year
€497,436
Staff costs
€4,129
Annual accounts
| Line | 2024 |
|---|---|
| Remuneration, social security and pensions62 | €4,129 |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €28,569 |
| Other operating charges640/8 | €1,766 |
| Gross operating margin9900 | -€6,385 |
| Operating profit (loss)9901 | -€40,850 |
| Financial income75/76B | €25,000 |
| Recurring financial income75 | €25,000 |
| Financial charges65/66B | €12,408 |
| Recurring financial charges65 | €12,408 |
| Profit (loss) for the period before taxes9903 | -€28,258 |
| Profit (loss) for the period9904 | -€28,258 |
| Profit (loss) for the period to be appropriated9905 | -€28,258 |
| Line | 2024 | |
|---|---|---|
| Assets | ||
| Total assets20/58 | €775,771 | |
| Fixed assets21/28 | €568,785 | |
| Intangible fixed assets21 | €200,468 | |
| Tangible fixed assets22/27 | €43,317 | |
| Plant, machinery and equipment23 | €29,454 | |
| Furniture and vehicles24 | €4,996 | |
| Other tangible fixed assets26 | €8,867 | |
| Financial fixed assets28 | €325,000 | |
| Current assets29/58 | €206,985 | |
| Stocks and contracts in progress3 | €61,595 | |
| Stocks30/36 | €61,595 | |
| Amounts receivable within one year40/41 | €108,045 | |
| Trade receivables40 | €63,248 | |
| Other amounts receivable41 | €44,797 | |
| Cash at bank and in hand54/58 | €37,345 | |
| Equity and liabilities | ||
| Total equity and liabilities10/49 | €775,771 | |
| Equity10/15 | €31,742 | |
| Contributions10/11 | €60,000 | |
| Profit (loss) carried forward14 | -€28,258 | |
| Amounts payable17/49 | €744,029 | |
| Amounts payable after more than one year17 | €497,436 | |
| Financial debts170/4 | €497,436 | |
| Amounts payable within one year42/48 | €236,906 | |
| Current portion of amounts payable after more than one year42 | €143,439 | |
| Trade debts44 | €93,467 | |
| Suppliers440/4 | €93,467 | |
| Taxes, remuneration and social security45 | €0 | |
| Remuneration and social security454/9 | €0 | |
| Accrued charges and deferred income492/3 | €9,687 | |
| Line | 2024 |
|---|---|
| Profit (loss) for the period9904 | -€28,258 |
| + Depreciation and write-downs630 | €28,569 |
| Operating cash flow (approximation) | €311 |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2025
03-10
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 64 days late
NBB filing
0 of 2 acts read
About the unread acts
We know of 2 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Namur · 1 establishment unit since 2024
Ground area
746 m²
Building footprint
77 m²
Volume, LiDAR
584 m³
2 parcels, Wallonia · tallest building 10.9 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
PHARMIDABLE
since 20242.360.526.276
2 parcels
Wallonia
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 92075A0211/00D009 | Wallonia | 607 m² | 1 · 22 m² | 7.3 m · 1 fl. |
| 52302A0041/00M000 | Wallonia | 139 m² | 1 · 55 m² | 10.9 m · 3 fl. |
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
Sovitalis
BE 0697.904.112
Herentals · Eq €31,728
Sièlimah
BE 0792.147.431
Charleroi · Eq €31,811
Babay Pharma
BE 1010.855.608
Sint-Joost-ten-Node · Eq €31,917
Make A Better Move
BE 0837.941.428
Genappe · Eq €31,465
HolsbeekVD Brecht
BE 0432.656.721
Brecht · Eq €32,260
Of 5,221 companies in sector 47730 we hold annual accounts for 3,860. 2,083 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded29-05-2024
Fiscal year end31-12
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
Scores and ratios are computed by Checked and are not a credit decision.